RESEARCH
RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRCA meta-analysis found that oncogenic driver mutations like RAS and BRAF may contribute to clinically meaningful differences in how MSI-H/dMMR metastatic colorectal cancer responds to immune checkpoint inhibitors, though these tumors are generally highly sensitive to immunotherapy. (Cancer Treatment Reviews)